BioCryst Pharmaceuticals Reports 57% Revenue Growth to $145.5 Million in Q1 2025

BioCryst Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly results, with total revenues reaching $145.5 million for the three months ended March 31, 2025, compared to $92.8 million during the same period in 2024. This 57% increase was primarily driven by a substantial rise in sales of its flagship product, ORLADEYO, which generated $120.2 million in the U.S. alone, up from $80.0 million in the previous year. The company also noted an increase in other revenues, particularly from peramivir sales, which contributed an additional $11.3 million.

In terms of profitability, BioCryst reported a net income of $32,000 for the first quarter of 2025, a notable turnaround from a net loss of $35.4 million in the prior year. This improvement was attributed to a combination of increased revenues and a reduction in research and development expenses, which fell to $37.3 million from $46.5 million, largely due to the completion of certain clinical trials and a decrease in costs associated with discontinued programs. Selling, general, and administrative expenses also rose to $82.5 million, reflecting the company's investment in commercial infrastructure to support ORLADEYO's growth.

Operationally, BioCryst has made strides in expanding its market presence. The company has successfully established reimbursement for ORLADEYO in all major Western European countries, except the Netherlands, which is expected to follow suit soon. Additionally, a recent market survey indicated that 97% of HAE treaters are considering prescribing ORLADEYO, with a significant increase in the likelihood of prescriptions among current prescribers. The company is also on track to submit a new drug application to the FDA for an oral granule formulation of ORLADEYO aimed at children aged 2 to 11.

As of March 31, 2025, BioCryst had total assets of $480.0 million, with cash and cash equivalents amounting to $105.2 million. The company’s liabilities totaled $932.0 million, leading to a stockholders' deficit of $451.9 million. The company has also made a partial prepayment of $75 million on its Pharmakon Loan Agreement, which reflects its ongoing efforts to manage its debt obligations effectively. Looking ahead, BioCryst anticipates that its financial resources will be sufficient to fund operations for at least the next 12 months, contingent on the continued success of its commercialization efforts and product development pipeline.